Back

hs-troponin should be used in unselected patients with suspected ACS. PRO.

3 March 2019 (09:00 - 09:12)
Organised by:
Congress Presentation Part of: Controversies in diagnostic strategies for chest pain patients Biomarkers ACVC Premium Access Acute Cardiovascular Care 2019

About the speaker

Photo
Professor Bertil Lindahl

Uppsala University, Uppsala (Sweden)

5 More presentations in this session

Presentation thumbnail
hs-troponin should be used in unselected patients with suspected ACS. CONTRA.
Professor M. Moeckel (Berlin, DE)
Slides Video
Presentation thumbnail
hs-troponin should be used in unselected patients with suspected ACS. Discussion.
Presentation thumbnail
We need to add a risk score to hs-troponin - PRO.
Doctor M. Tubaro (Rome, IT)
Slides Video
Presentation thumbnail
We need to add a risk score to hs-troponin - CONTRA.
Professor J. Boeddinghaus (Basel, CH)
Slides Video
Presentation thumbnail
We need to add a risk score to hs-troponin - Discussion.

Access the full session

Session thumbnail
Controversies in diagnostic strategies for chest pain patients

The Event

Event poster

Acute Cardiovascular Care 2019

3 March 2019 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Usefulness of early measurement of NT-proBNP and troponin in patients presenting with or without ST-segment elevation acute coronary syndrome
21 May 2023
thumbnail
Congress Session
Recent advances in clinical practice guidelines: what the imager needs to know and apply - Part 2
12 December 2024
thumbnail
Congress Session
Challenges and innovations in cardiovascular risk stratification with cardiac biomarkers
3 April 2025
thumbnail
Congress Presentation
Cardiac troponins and anthracycline cardiotoxicity: a sub study of the PROACT trial; are all assays made equal?
21 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources